Replies to post #9284 on GTC Biotherapeutics (fka GTCB)

[keitern]

>GTC methods aren't cheap when you factor in having to get approved on a new method of production<<

Just to elaborate, I thought bio-reactors cost as much as 600mil and that GTC's cost 60mil, leaving a lot of margin for "issues" with respect to the novel platform. Also, GTC's is expandable from its established base. For example, re. AAT, I think they already have the manufacturing marked out with high yield. I am naive, but it seems perfect to me.

Not picking a fight, genuinely interested in learning - thanks.

[DragonBits]

keitern, we were talking about how safe GTC was. My point was that with about 8.5 million in debt and 16 million in cash, GTC has no flexibity should some issue arrise. So in that regard there is a serious danger.

There is no way to quantify the possiblity of an unexpected issue.

What would help is a lot more cash on the books.